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Transcription controlled by Steroid Hormone Receptors (SHRs) plays a key role in many important physiological
processes like organ development, metabolite homeostasis, and response to external stimuli. Understandably,
the members of this family have drawn a lot of attention from the scientific community since their discovery,
four decades ago. Still, after many years of research we are only beginning to unravel the complex nature of
these receptors.The pace at which we do has improved significantly in recent years with the discovery of
genetically encoded fluorescent probes, and the accompanying revival of biophysical approaches that allow
more detailed study of SHRs. Here, we will look into the different aspects of SHR signalling, and discuss how
biophysical techniques have contributed to visualizing their function in their native context, the living cell.
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Steroid hormone receptors
As early as 1896, Thomas Beatson described that
removal of the ovaries in advanced breast cancer patients
often resulted in remarkable improvement [Beatson,
1896].With that he had revealed the stimulating effect of
the female ovarian hormone estrogen on breast cancer,
even before the hormone itself was discovered. His work
provided a foundation for the modern use of hormone
therapy in treatment and prevention of breast cancer.
Only much later was the cellular counterpart that mediated
the described effects revealed, the estrogen receptor
(ER) [Green et al., 1986; Jensen, 1962].
As it turned out, this receptor plays a key role in the
development and maintenance of the sexual reproductive
tissues, and therefore, as Beatson had discovered, in
breast cancer as well.We now know that the estrogen
receptor is part of the nuclear receptor superfamily, and
comes in two forms, ERα [NR3A1] and ERβ [NR3A2].
More specifically, both receptors are members of the
subgroup of Steroid Hormone Receptors (SHRs), to which
the cortisol binding glucocorticoid receptor (GR) [NR3C1],
the aldosterone binding mineralocorticoid receptor (MR)
[NR3C2], the progesterone receptor (PR) [NR3C3], and
the dihydrotestosterone (DHT) binding androgen receptor
(AR) [NR3C4] also belong (Figure 1A).
In addition, the SHR subgroup contains three orphan
receptors closely related to ER: the estrogen related
receptors α (ERRα) [NR3B1], β (ERRβ) [NR3B2], and γ
(ERRγ) [NR3B3], for which a natural ligand remains to
be identified. All SHRs function as nuclear transcription
factors whose activity is regulated by small lipid-soluble
ligands, and each member plays an important role in key
physiological processes like reproduction, glucose
metabolism, salt balance, and stress response.
Figure 1. Overview of the steroid hormone receptor family. A.
Phylogenetic tree of the Steroid Hormone Receptor (SHR) family showing
the evolutionary interrelationships and distance between the various
receptors. Based on alignments available at The NucleaRDB [Horn et al.,
2001]. B. All steroid receptors are composed of a variable N-terminal
domain (A/B) containing the AF-1 transactivation region, a highly
conserved DNA Binding Domain (DBD), a flexible hinge region (D), and
a C-terminal Ligand Binding Domain (LBD, E) containing the AF-2
transactivation region.The estrogen receptor α is unique in that it contains
an additional C-terminal F domain. Numbers represent the length of the
receptor in amino acids.
Structural overview
The members of the Steroid Hormone Receptor family
share a similar, modular architecture, consisting of a
number of independent functional domains (Figure 1B).
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domain (DBD) containing the characteristic zinc-finger
motifs.The DBD is followed by a flexible hinge region
and a moderately conserved Ligand Binding Domain
(LBD), located at the carboxy-terminal end of the receptor.
The estrogen receptor α is unique in that it contains an
additional F domain of which the exact function is unclear.
The LBD is composed of twelve α-helices (H1-H12) that
together fold into a canonical α-helical sandwich. Besides
its ligand binding capability, the LBD also plays an
important role in nuclear translocation, chaperone binding,
receptor dimerization, and coregulator recruitment through
its potent ligand-dependent transactivation domain,
referred to as AF-2. A second, ligand independent,
transactivation domain is located in the more variable
N-terminal part of the receptor, designated as AF-1.To
date, no crystal structure of a full-length SHR exists,
though structures of the DBD and LBD regions of most
SHRs are available.These have helped significantly in
understanding the molecular aspects of DNA and ligand
binding, but have to some extent also led to biased
attention to these parts of the receptor only. For example,
many coregulator interaction studies are still performed
with the LBD only, while numerous studies have
demonstrated that the AF-2 domain often tells only part
of the story.With the help of biophysical techniques,
however, it is feasible to study the full-length receptor in
its native environment (Figure 2).
Ligand binding
Steroid Hormones (SHs) reach their target cells via the
blood, where they are bound to carrier proteins. Because
of their lipophilic nature it is thought that they pass the
cell membrane by simple diffusion, although some
evidence exists that they can also be actively taken up
by endocytosis of carrier protein bound hormones
[Hammes et al., 2005]. For a long time it has been
assumed that binding of the ligand resulted in a simple
on/off switch of the receptor (Figure 2, step 1).While this
is likely the case for typical agonists like estrogen and
progesterone, this is not always correct for receptor
antagonists.These antagonists come in two kinds,
so-called partial antagonists (for the estrogen receptors
known as SERMs for Selective Estrogen Receptor
Modulators) and full antagonists.The partial antagonist
can, depending on cell type, act as a SHR agonist or
antagonist. In contrast, full antagonists (for ER known as
SERDs for Selective Estrogen Receptor Downregulators)
always inhibit the receptor, independent of cell type, in
part by targeting the receptor for degradation. Binding of
either type of antagonist results in major conformational
changes within the LBD and in release from heat shock
proteins that thus far had protected the unliganded
receptor from unfolding and aggregation (Figure 2, step
2).This process was nicely visualized for the estrogen
receptor by Devin-Leclerc et al., who showed using
fluorescence microscopy that the nuclear ER-HSP90
complex dissociates after addition of either agonist or
antagonist, followed by rapid relocation of the heat shock
protein to the cytoplasm [Devin-Leclerc et al., 1998].
Nuclear translocation
The constitutive nuclear localisation of ER is a unique
feature of this SHR only. Although family members, SHRs
are located differently in cells.The subcellular localisation
of SHRs in living cells has been extensively studied using
fusion constructs of green fluorescent protein (GFP).This
showed that SHRs can be divided in three groups based
on their unliganded distribution: ERα and ERβ are found
predominantly in the nucleus [Htun et al., 1999], GR and
AR are found primarily in the cytoplasm [Georget et al.,
1997; Htun et al., 1996], while MR and PR have a mixed
distribution over both cytoplasm and nucleus [Fejes-Toth
et al., 1998; Lim et al., 1999].The progesterone receptor
is of particular interest as it exists in two forms with
different ratios of nuclear versus cytoplasmic localization
of the unliganded receptor. In most cell contexts, the PRA
isoform is a repressor of the shorter PRB isoform, and
without hormone induction it is mostly located in the
nucleus, whereas PRB distributes both in the nucleus
and in the cytoplasm. PRB accumulates in the nucleus
after progesterone binding, a process that directly
correlates with PR mediated transcription [Li et al., 2005;
Lim et al., 1999].
Rapid and almost complete nuclear translocation following
ligand addition is a common behavior observed for almost
all SHRs (Figure 2, step 3).This translocation coincides
with a striking alteration in receptor distribution within the
nucleus, most apparent in the case of the already nuclear
ER. Htun et al., observed that GFP-ER’s uniform
distribution changes into a punctate pattern upon the
addition of either agonistic or antagonistic ligands [Htun
et al., 1999]. A few years earlier the same group had
already made similar observations for GFP-GR [Htun et
al., 1996]. Other groups confirmed similar behavior for
the other SHRs, some directly by tagging two receptors
with different variants of GFP and following both at the
same time [Nishi et al., 2001]. Fejes-Toth and colleagues
demonstrated that hormone-activated MRs accumulated
in dynamic, discrete clusters in the cell nucleus, a
phenomenon that only concurred with agonistic
mineralocorticoids and not with full antagonists
[Fejes-Toth et al., 1998]. Further work on MR and AR
showed that the accumulation of these receptors in about
250-400 foci requires both the DBD and LBD regions,
and is possibly influenced by AF-1 function [Farla et al.,
2005; Goto et al., 2003; Pearce et al., 2002;Tomura et
al., 2001;Tyagi et al., 2000].The exact nature of these
foci is still unclear and multiple roles have been proposed,
including storage depots and sites of transcription,
splicing, aggregation or degradation.What is clear,
however, is that nuclear and subnuclear translocation of
SHRs is ligand and concentration dependent. Martinez
et al., recently made use of this finding to devise a
molecular screen for ER ligands based on a fluorescent
GR-ER chimera [Martinez et al., 2005]. Instead of a
constitutive nuclear localization, this chimeric receptor
adapted the cytoplasmic localization of unliganded GR,
and translocates to the nucleus upon ER ligand addition.
Interestingly, the GR-ER chimera retained the (anti-)
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Review Visualizing steroid hormone receptorsFigure 2. Steroid hormone receptor signalling. Steroid Hormone Receptors (SHR) act as hormone dependent nuclear transcription factors. Upon
entering the cell by passive diffusion, the hormone (H) binds the receptor, which is subsequently released from heat shock proteins, and translocates
to the nucleus.There, the receptor dimerizes, binds specific sequences in the DNA, called Hormone Responsive Elements or HREs, and recruits a
number of coregulators that facilitate gene transcription.This latter step can be modulated by receptor antagonists like tamoxifen (T), and cellular
signalling pathways. Examples of processes studied using biophysical techniques and discussed in this review include: hormone binding (1), chaperone
interaction (2), nuclear translocation (3), receptor dimerization (4), DNA binding (5), putative membrane-bound receptors (6), coregulator recruitment
(7), transcription (8), proteasomal degradation (9), modulation by cellular signalling pathways (10), and antagonist resistance (11).
estrogen binding properties, and could thus be used to
screen for new ER ligands.
Dimerization
Nuclear receptors that bind steroid hormones typically
form homodimers (Figure 2, step 4). Dimer formation is
facilitated mainly through interactions between the LBDs
of both receptors, and is essential for their function, as
mutations in the dimerization domain typically render the
receptor inactive. ER has been reported to exist as a
dimer even in the absence of ligand, although it is
important to note that these studies have again been
performed with the LBD domain only [Salomonsson et
al., 1994]. Biophysical in vitro studies, again with the LBD
only, have confirmed these data and show slow
dissociation of unliganded dimers, which is further
retarded by ligand binding [Tamrazi et al., 2002]. Recent
in vivo studies suggested that this might not hold for
full-length receptors though, at least not for AR. Schaufele
et al., used Fluorescence Resonance Energy Transfer
(FRET) to study AR dimer formation [Schaufele et al.,
2005]. FRET is the radiationless transfer of energy from
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fluorophore [Förster, 1948]. Importantly, FRET is
extremely sensitive to the distance between the
fluorophores (its efficiency decays with the distance to
the sixth power), and will therefore only occur when two
proteins are on average no more than one molecule in
distance apart, but usually they interact directly (Figure
3A). Schaufele and colleagues measured FRET between
CFP and YFP labeled AR receptors, and their results
suggest that dimerization only takes place after ligand
binding, and predominantly in the nucleus. It should be
noted that absence of FRET does not imply absence of
protein-protein interaction since the relative orientation
of two fluorophores is also critical for FRET to occur
[Förster, 1948]. Further study is required to confirm these
findings and to determine whether this behavior is unique
for AR or also applies to other SHRs.
Dimers of SHRs are only efficiently formed between
closely related receptors. In this light the previously
mentioned two isoforms of the progesterone receptor and
the two estrogen receptors are of particular interest. In
both cases one of the two seems to exhibit a repressive
function on the other. ERβ efficiently dimerizes with ERα
and mixed dimers show identical subnuclear distribution
as homodimers [Matsuda et al., 2002]. However, binding
of ERβ suppresses ERα mediated gene transcription,
and accordingly, the mouse knockouts of either receptor
show completely opposing phenotypes [Couse and
Korach, 1999].
DNA binding
Upon binding of ligand and translocation to the nucleus,
SHRs bind to specific regions in the DNA called Hormone
Responsive Elements (HREs) through zinc-finger motifs
present in the DBD (Figure 2, step 5).The exact mode
of binding has been characterised in detail with help of
available crystal structures and extensive biophysical in
vitro measurements. Consensus nucleotide binding
sequences have been determined for all SHRs, but these
show a significant amount of ambiguity, making it hard
to pinpoint true target HREs in the genome. A HRE is
made up of two so-called half-sites that each bind one
monomer of the SHR dimer. Interestingly, single half-sites
have also been found in genes that clearly respond to
hormone, hinting at a possible role for receptors in their
monomeric configuration.
Immobilization of SHRs on DNA and other nuclear
structures has been studied with photobleaching
techniques like Fluorescence Recovery After
Photobleaching (FRAP). By bleaching fluorescent
molecules in a region of interest in a living cell and
measuring recurrence of fluorescence levels in the
bleached area, the mobility of the tagged molecules can
be determined (Figure 4). Using this technique several
groups were able to demonstrate a clear correlation
between receptor immobilization in the nucleus and the
appearance of the typical punctate receptor distribution,
which was most convincingly demonstrated by Schaaf
and colleagues who compared 13 GR ligands [Schaaf et
al., 2005]. FRAP measurements show that fluorescently
tagged SHRs such as ER, GR, and AR are highly mobile
and dynamic in the unliganded state, whereas
ligand-bound forms are less mobile [Farla et al., 2004;
Sprague et al., 2004; Stenoien et al., 2001b]. Stenoien
et al., further showed that in the case of ERα, FRAP could
discriminate between ligands with potential agonistic
properties and full antagonists on the basis of receptor
immobilization in the nucleus [Stenoien et al., 2001b].
The nature of the substrate on which the receptor
immobilizes remains uncertain, but almost certainly
includes DNA. Carefully controlled FRAP measurements
from Sprague et al., show that in free form GR is bound
to a single type of substrate, most probably DNA, with
each molecule binding on average 65 sites per second
[Sprague et al., 2004].This rapid sampling of GR is likely
to be important in finding a specific HRE. Upon ligand
binding, the residence time on DNA is significantly
increased. According to Farla et al., on average one out
of five ARs is immobilized in the presence of ligand, each
individual AR being immobile for 1-2 min.This
immobilization is dependent on DNA binding since
GFP-ARs mutated in the DNA-binding domain were not
immobilized [Farla et al., 2004]. Likewise, FRAP analysis
by Kino et al., on several GR mutant receptors showed
a significantly increased nuclear motility and decreased
chromatin retention, which correlated with impaired
transcriptional activity [Kino et al., 2004].
DNA binding and transcription has been visualized directly
by using cells that have stably integrated a tandem array
of HREs. Pioneering work in this area has been performed
by the Hager lab, which used this approach to study the
interaction of GR with a natural promoter [McNally et al.,
2000].The promoter array allows significant amounts of
GFP-GR to accumulate for direct detection under the
microscope.The recruitment of GFP-GR leads to gross
alterations in chromatin structure of the array that
correlate with gene transcription [Muller et al., 2001].
Interestingly, FRAP analysis on the array again shows a
rapid exchange of receptors between chromatin and the
nucleoplasmic compartment. Further analysis
demonstrated that following binding of GR to the
promoter, the receptor is actively displaced from the
template during a chromatin remodeling reaction
facilitated by the hSWI/SNF complex [Nagaich et al.,
2004]. Further evidence comes from work on PR by the
same group, which showed that the exchange of PR-GFP
on the array was slowed down (but still in the order of
seconds) upon agonist addition, and even further slowed
down after addition of a partial antagonist [Rayasam et
al., 2005]. Strikingly, addition of a full-antagonist showed
the opposite effect, with ongoing exchange at a rate faster
than for an agonist bound receptor. In contrast to an
agonist or partial antagonist bound receptor, addition of
a full-antagonist does not lead to recruitment of the
SWI/SNF chromatin remodeling complex, which may
partly explain the above results.Together, these findings
have led to the so-called hit-and-run model. In contrast
to static binding of the receptor to a HRE and the
subsequent build up of the transcription complex, this
model suggests a receptor continuously probes the DNA
for potential binding sites.Transcriptional activation
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05003 | Page 4 of 9
Review Visualizing steroid hormone receptorsFigure 3. Fluorescence resonance energy transfer (FRET). A. Principle of FRET to measure intermolecular interaction. Exciting the blue variant
of GFP (CFP) linked to one Steroid Hormone Receptor (SHR) monomer at 435nm results in emission at 475nm, unless energy is transferred to a SHR
monomer coupled to the yellow variant of GFP (YFP).This phenomenon only occurs when both monomers physically interact as a dimer, and results
in increased YFP emission at 525nm at the cost of CFP emission at 475nm. B. A similar protocol is followed to measure intramolecular FRET. A single
SHR monomer is tagged with two variants of GFP. Ligand binding induces conformational changes within the receptor and alters the relative orientation
and distance between the two fluorophores, leading to changes in FRET efficiency. C. A confocal microscopy image showing U2OS cells expressing
nuclear YFP-ER-CFP to monitor conformational changes through intramolecular FRET. Fluorescence is depicted in false colors. D. An example FRET
trace, measuring intramolecular FRET between CFP and YFP within a single nucleus of a YFP-ER-CFP expressing cell as shown in 3C.The fluorescent
signal of YFP (yellow) and CFP (cyan) is arbitrarily set to the same level such that the ratio (red) is 1, and followed in time. After 80 seconds, tamoxifen
is added to the cells (arrowhead) and a conformational change is observed in the form of a change in FRET; the YFP signal increases at the cost of
CFP fluorescence.
Figure 4. Fluorescence recovery after photobleaching (FRAP). By bleaching the indicated (blue) region in the fluorescent area (here the nucleus
of a cell expressing ERα fused to GFP) at time t0, fluorescence decreases from the initial fluorescence Fi to F0.The fluorescence recovers over time
by diffusion.The characteristic diffusion time τD indicates the time at which half of the fluorescence has recovered.The mobile fraction can be calculated
by comparing the fluorescence in the bleached region after full recovery (Fω) with the fluorescence in a distant region in the nucleus (red, dashed line).
reflects the probability that all components required for
activation will meet at a certain chromatin site.
Besides binding to Hormone Responsive Elements, SHRs
can also exert their effects by binding directly to other
transcription factors. For example, ERα is able to bind to
fos/jun, and thus regulate AP-1 mediated transcription of
genes like cyclin D1. Similarly, ERα can bind Sp1 proteins
and regulate transcription of genes that contain a Sp1/ER
binding site. Interestingly, antagonists often have agonistic
effects in this setting, which may be important when it
comes to resistance to antagonistic compounds.This is
illustrated by work from Kim et al., who used FRET to
visualize the interaction between ERα and Sp1 [Kim et
al., 2005]. Addition of the full anti-estrogen ICI 182,780
inhibits normal ERα mediated transcription, yet like
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and Sp1 that correlated with Sp1 mediated transcription
of a reporter construct.
Recently a number of groups have claimed a role for
SHRs in non-genomic, extranuclear signalling events
(Figure 2, step 6).Targeting ERα artificially to the plasma
membrane has a marked influence on ERK1/2 signalling,
which was not affected by full anti-estrogens [Rai et al.,
2005]. Similar effects on the Mitogen Activated Protein
Kinase (MAPK) and Protein Kinase A (PKA) pathways
have also been attributed to the wildtype receptor [Levin,
2005; Razandi et al., 2004]. However, most studies are
based on biochemical approaches where post-lysis
artefacts are hard to exclude. Moreover, convincing
microscopic pictures of SHR membrane localization are
still lacking. Nevertheless, accumulating evidence seems
to point to possible functions for SHRs other than those
mediated by DNA binding.
Coregulator recruitment
The classical mode of action of SHRs involves ligand and
DNA binding. For transcription to occur the subsequent
recruitment of coregulator proteins is absolutely required
(Figure 2, step 7).These regulatory proteins come in two
types, coactivators and corepressors that respectively
enhance or diminish transactivation activity through
various enzymatic activities, including acetylating,
deacetylating, methylating, ubiquitinating, and kinase
activity. Ligand dependent recruitment of coregulators
occurs through a hydrophobic cleft formed by helices 3,
4 and 12 in the AF-2 domain of the receptor [Gronemeyer
et al., 2004]. In free receptors this pocket is shielded by
a short amphipathic α-helix (H12) located at the
carboxy-terminal end of the receptor that prevents AF-2
mediated coregulator binding in the absence of ligand.
Upon hormone binding, this helix is repositioned, which
opens a functional interface for coregulator recruitment
through conserved LXXLL motifs in the cofactor.
Antagonists exert their function by inducing a different
conformational change of H12 that blocks or modulates
the recruitment of these essential coregulators. However,
not all coregulator binding occurs through the AF-2 region.
Other conformational changes within the receptor and
events like dimerization are also likely to be involved in
coregulator recruitment. Moreover, the AF-1 region of
SHRs plays an important role in ligand independent
binding of coregulators.The exact coregulator
requirements for transcription are dependent on cell type,
and probably also on ligand and promoter context.This
explains why partial antagonists can have antagonistic
properties in one tissue, while exhibiting agonistic
properties in another.
The most well studied coactivators are of the Steroid
Receptor Coactivator (SRC) family, which includes SRC-1
(or NcoA-1), SRC-2 (also known as TIF-2 or GRIP1,
NcoA-2) and SRC-3 (also known as RAC3, ACTR, AIB1,
P/CIP and TRAM). Llopis et al., were the first to directly
visualize the interaction between SRC-1 and a SHR in
living cells using FRET [Llopis et al., 2000].They showed
that the ERα LBD exhibited some basal interaction with
coactivators in unstimulated cells that was increased upon
agonist addition and abolished by receptor antagonists.
A large number of publications have since confirmed
these findings, also with full-length ER constructs.
Interestingly, these studies clearly show that the receptor
adopts a slightly different conformation for various ligands,
and this conformation significantly influences the binding
of specific coregulatory proteins [Schaufele et al., 2000;
Tamrazi et al., 2005;Weatherman et al., 2002]. Likewise,
the small structural differences between the LBD of ERα
and ERβ can result in profound differences in SRC-1
recruitment with the same ligand [Margeat et al., 2003].
We have visualized these conformational changes by
fusing full-length ERα with YFP to its N- and CFP to its
C-terminus [Michalides et al., 2004].This allowed us to
monitor conformational alterations of the receptor after
ligand binding in the form of a change in FRET between
CFP and YFP (Figure 3B-D). Indeed, subtle FRET
differences between the various anti-estrogens tested
were observed, showing that the receptor had adopted
ligand specific conformations.
The stoichiometry of interaction between ERα and SRC-1
was studied using fluorescence correlation spectroscopy
(FCS). By measuring the fluorescence signal from a very
small excitation volume only, this technique allows precise
determination of the diffusion coefficient of fluorescently
labeled proteins, which is in part dependent on protein
complex formation (Figure 5). In this way, Margeat et al.,
could show that the ERα dimer binds a single SRC-1
coactivator molecule [Margeat et al., 2001].
One caveat of the above experiments is the use of only
the AF-2 binding part of SRC-1.This may give false
impressions when conclusions are extrapolated to the
full-length receptor.Work from others and unpublished
data from our lab have demonstrated that full-length
SRC-1 binds the receptor through its AF-1 domain in a
ligand independent manner [Dutertre and Smith, 2003]
(Zwart et al., manuscript in preparation). AF-2 binding
still functions as a switch to invoke full transactivation
activity, but in contrast to what the above studies suggest,
SRC-1 is already bound to unliganded receptors.This
was also demonstrated by Stenoien et al., who used a
fusion construct of CFP-ERα with a lac repressor domain
to artificially target the receptor to an integrated lac
operator array [Stenoien et al., 2001a]. Even in the
absence of ligand, significant levels of SRC-1 were
already present on the array, which further increased
upon addition of agonist, and decreased after addition of
antagonist. Further work by this group suggested that
agonist binding predominantly stabilized SRC-1 binding,
which translated in identical mobility of both proteins
[Stenoien et al., 2001b]. Similar results were reported for
other SHRs like GR and AR, and for other coregulators
including CREB binding protein (CBP), glucocorticoid
receptor (GR) interacting protein 1 (GRIP-1), and RIP140
[Becker et al., 2002; Carascossa et al., 2006; Marcelli et
al., 2006]. Interestingly, in all cases dynamic DNA binding
of SHRs was observed even in the presence of agonist
and coregulators.
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Review Visualizing steroid hormone receptorsFigure 5. Fluorescence correlation spectroscopy (FCS). By using the microscope objective lens to focus the laser beam, a diffraction limited
excitation volume is created.The emitted fluorescence signal (F) from this observation volume fluctuates as labeled molecules diffuse in and out, and
the duration of the fluctuations are related to the average time individual models reside within the volume. One such an event is depicted in the graph.
The residence time can be used to determine the diffusion coefficient for the fluorescent molecules, which is dependent on their size and interaction
with other proteins. For example, it can be used to discriminate monomeric Steroid Hormone Receptors (SHRs, A) from dimeric complexes (B).
Transcription
Our view on SHR mediated transcription has more and
more shifted from one in which a static holoenzyme of
transcription factors is steadily built up after initial binding
of the receptor to a response element, into a highly
dynamic picture where different factors rapidly move in
and out to perform temporary and local functions (Figure
2, step 8). In this so-called hit-and-run model, transcription
only takes place when all factors coincidentally meet at
the same time at the same location. Factors like DNA
binding on specific HREs, and ligand dependent
coregulator recruitment simply increase the odds that a
successful transcriptional unit is formed and a gene is
transcribed. FRAP analysis shows that indeed the majority
of nuclear proteins are highly mobile [Phair and Misteli,
2000], except for Polymerase II, which once recruited has
a residence time on the DNA in the order of minutes.
Whichever model is closer to reality, it is clear that
transcription is a complex process, requiring dozens of
proteins. Large-scale Chromatin IP assays have shown
the recruitment of at least 46 factors to an empty promoter
before continued transcription can take place [Metivier et
al., 2003]. Interestingly, these experiments revealed a
striking ATP-dependent periodicity in the recruitment of
these factors, which was confirmed using FRAP analysis
[Metivier et al., 2003; Reid et al., 2003].The observed
cycling time was in the order of 1h, much slower than the
rapid exchange of SHRs on the template described
earlier. Receptor degradation by the proteasome plays
an important role in this process, as a block of
proteasomal function halts the cycle after one round of
transcription (Figure 2, step 9).This corresponds to
previous observations that GR and ERα completely
immobilize in the nucleus upon proteasome inhibition
[Stavreva et al., 2004; Stenoien et al., 2001b]. However,
since proteasome inhibition rapidly de-ubiquitinates
histones, these effects may also be indirect, and the result
of chromatin alterations [Dantuma et al., 2006]. An
important role to maintain proper cycling has also been
suggested for heat shock proteins like HSP-90 [Stavreva
et al., 2004].
The exact role of this cyclic recruitment of transcription
factors to the promoter is still unclear. It is also difficult to
interpret how this slower cycle relates to the rapid
exchange of SHRs that forms the basis of the hit-and-run
model. Interestingly, the cyclic pattern of transcription
factor presence on the promoter does suggest that some
form of order in the build up of a functional transcriptional
unit must exist, resulting in a so-called transcription
factory.This may very well represent the summation of
all rapid exchange events over a longer period of time,
which suggests that both models may not necessarily be
mutually exclusive, and might act in subsequent steps of
transcription initiation.
Note
The literature on steroid hormone receptors is extensive
and only selected studies were cited in this review due
to space limitations.We sincerely apologize to all
investigators whose work was not mentioned.
References
Beatson, G.W. (1896) On the treatment of inoperable cases of carcinoma
of the mamma: suggestions for a new method of treatment with illustrative
cases. Lancet 2, 104-107.
Becker, M., Baumann, C., John, S., Walker, D. A., Vigneron, M., McNally,
J. G. and Hager, G. L. (2002) Dynamic behavior of transcription factors
on a natural promoter in living cells EMBO Rep 3, 1188-94.
Carascossa, S., Gobinet, J., Georget, V., Lucas, A., Badia, E., Castet,
A., White, R., Nicolas, J. C., Cavailles, V. and Jalaguier, S. (2006) Rip140
Is a Repressor of the Androgen Receptor Activity Mol Endocrinol 20,
1506-1518.
Couse, J. F. and Korach, K. S. (1999) Estrogen receptor null mice: what
have we learned and where will they lead us? Endocr Rev 20, 358-417.
Dantuma, N. P., Groothuis, T. A., Salomons, F. A. and Neefjes, J. (2006)
A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin
remodeling J Cell Biol 173, 19-26.
Devin-Leclerc, J., Meng, X., Delahaye, F., Leclerc, P., Baulieu, E. E. and
Catelli, M. G. (1998) Interaction and dissociation by ligands of estrogen
receptor and Hsp90: the antiestrogen RU 58668 induces a protein
synthesis-dependent clustering of the receptor in the cytoplasm Mol
Endocrinol 12, 842-54.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05003 | Page 7 of 9
Review Visualizing steroid hormone receptorsDutertre, M. and Smith, C. L. (2003) Ligand-independent interactions of
p160/steroid receptor coactivators and CREB-binding protein (CBP) with
estrogen receptor-alpha: regulation by phosphorylation sites in the A/B
region depends on other receptor domains Mol Endocrinol 17, 1296-314.
Farla, P., Hersmus, R., Trapman, J. and Houtsmuller, A. B. (2005)
Antiandrogens prevent stable DNA-binding of the androgen receptor J
Cell Sci 118, 4187-98.
Farla, P., Hersmus, R., Geverts, B., Mari, P. O., Nigg, A. L., Dubbink, H.
J., Trapman, J. and Houtsmuller, A. B. (2004) The androgen receptor
ligand-binding domain stabilizes DNA binding in living cells J Struct Biol
147, 50-61.
Fejes-Toth, G., Pearce, D. and Naray-Fejes-Toth, A. (1998) Subcellular
localization of mineralocorticoid receptors in living cells: effects of receptor
agonists and antagonists Proc Natl Acad Sci U S A 95, 2973-8.
Förster, T. (1948) Zwischenmolekulare energiewandering und fluoreszenz.
Annalen Physik 6, 55-75.
Georget, V., Lobaccaro, J. M., Terouanne, B., Mangeat, P., Nicolas, J.
C. and Sultan, C. (1997) Trafficking of the androgen receptor in living
cells with fused green fluorescent protein-androgen receptor Mol Cell
Endocrinol 129, 17-26.
Goto, K., Zhao, Y., Saito, M., Tomura, A., Morinaga, H., Nomura, M.,
Okabe, T., Yanase, T., Takayanagi, R. and Nawata, H. (2003) Activation
function-1 domain of androgen receptor contributes to the interaction
between two distinct subnuclear compartments J Steroid Biochem Mol
Biol 85, 201-8.
Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J. M., Argos, P. and
Chambon, P. (1986) Human oestrogen receptor cDNA: sequence,
expression and homology to v-erb-A Nature 320, 134-9.
Gronemeyer, H., Gustafsson, J. A. and Laudet, V. (2004) Principles for
modulation of the nuclear receptor superfamily Nat Rev Drug Discov 3,
950-64.
Hammes, A., Andreassen, T. K., Spoelgen, R., Raila, J., Hubner, N.,
Schulz, H., Metzger, J., Schweigert, F. J., Luppa, P. B., Nykjaer, A. and
Willnow, T. E. (2005) Role of endocytosis in cellular uptake of sex steroids
Cell 122, 751-62.
Htun, H., Holth, L.T., Walker, D., Davie, J. R. and Hager, G. L. (1999)
Direct visualization of the human estrogen receptor alpha reveals a role
for ligand in the nuclear distribution of the receptor Mol Biol Cell 10,
471-86.
Htun, H., Barsony, J., Renyi, I., Gould, D. L. and Hager, G. L. (1996)
Visualization of glucocorticoid receptor translocation and intranuclear
organization in living cells with a green fluorescent protein chimera Proc
Natl Acad Sci U S A 93, 4845-50.
Jensen, E.V. (1962) On the mechanism of estrogen action Perspect Biol
Med 6, 47-59.
Kim, K., Barhoumi, R., Burghardt, R. and Safe, S. (2005) Analysis of
estrogen receptor alpha-Sp1 interactions in breast cancer cells by
fluorescence resonance energy transfer Mol Endocrinol 19, 843-54.
Kino, T., Liou, S. H., Charmandari, E. and Chrousos, G. P. (2004)
Glucocorticoid receptor mutants demonstrate increased motility inside
the nucleus of living cells: time of fluorescence recovery after
photobleaching (FRAP) is an integrated measure of receptor function Mol
Med 10, 80-8.
Levin, E. R. (2005) Integration of the extranuclear and nuclear actions of
estrogen Mol Endocrinol 19, 1951-9.
Li, H., Fidler, M. L. and Lim, C. S. (2005) Effect of initial subcellular
localization of progesterone receptor on import kinetics and transcriptional
activity Mol Pharm 2, 509-18.
Lim, C. S., Baumann, C.T., Htun, H., Xian, W., Irie, M., Smith, C. L. and
Hager, G. L. (1999) Differential localization and activity of the A- and
B-forms of the human progesterone receptor using green fluorescent
protein chimeras Mol Endocrinol 13, 366-75.
Llopis, J., Westin, S., Ricote, M., Wang, Z., Cho, C.Y., Kurokawa, R.,
Mullen, T. M., Rose, D.W., Rosenfeld, M. G., Tsien, R.Y. and Glass, C.
K. (2000) Ligand-dependent interactions of coactivators steroid receptor
coactivator-1 and peroxisome proliferator-activated receptor binding
protein with nuclear hormone receptors can be imaged in live cells and
are required for transcription Proc Natl Acad Sci U S A 97, 4363-8.
Marcelli, M., Stenoien, D. L., Szafran, A.T., Simeoni, S., Agoulnik, I. U.,
Weigel, N. L., Moran, T., Mikic, I., Price, J. H. and Mancini, M. A. (2006)
Quantifying effects of ligands on androgen receptor nuclear translocation,
intranuclear dynamics, and solubility J Cell Biochem 98, 770-788.
Margeat, E., Bourdoncle, A., Margueron, R., Poujol, N., Cavailles, V. and
Royer, C. (2003) Ligands differentially modulate the protein interactions
of the human estrogen receptors alpha and beta J Mol Biol 326, 77-92.
Margeat, E., Poujol, N., Boulahtouf, A., Chen, Y., Muller, J. D., Gratton,
E., Cavailles, V. and Royer, C. A. (2001) The human estrogen receptor
α dimer binds a single SRC-1 coactivator molecule with an affinity dictated
by agonist structure J Mol Biol 306, 433-42.
Martinez, E. D., Rayasam, G.V., Dull, A. B., Walker, D. A. and Hager,
G. L. (2005) An estrogen receptor chimera senses ligands by nuclear
translocation J Steroid Biochem Mol Biol 97, 307-21.
Matsuda, K., Ochiai, I., Nishi, M. and Kawata, M. (2002) Colocalization
and ligand-dependent discrete distribution of the estrogen receptor
(ER)alpha and (ER)beta Mol Endocrinol 16, 2215-30.
McNally, J. G., Muller, W. G., Walker, D., Wolford, R. and Hager, G. L.
(2000) The glucocorticoid receptor: rapid exchange with regulatory sites
in living cells Science 287, 1262-5.
Metivier, R., Penot, G., Hubner, M. R., Reid, G., Brand, H., Kos, M. and
Gannon, F. (2003) Estrogen receptor-alpha directs ordered, cyclical, and
combinatorial recruitment of cofactors on a natural target promoter Cell
115, 751-63.
Michalides, R., Griekspoor, A., Balkenende, A., Verwoerd, D., Janssen,
L., Jalink, K., Floore, A., Velds, A., van't Veer, L. and Neefjes, J. (2004)
Tamoxifen resistance by a conformational arrest of the estrogen receptor
alpha after PKA activation in breast cancer Cancer Cell 5, 597-605.
Muller, W. G., Walker, D., Hager, G. L. and McNally, J. G. (2001)
Large-scale chromatin decondensation and recondensation regulated by
transcription from a natural promoter J Cell Biol 154, 33-48.
Nagaich, A. K., Walker, D. A., Wolford, R. and Hager, G. L. (2004) Rapid
periodic binding and displacement of the glucocorticoid receptor during
chromatin remodeling Mol Cell 14, 163-74.
Nishi, M., Ogawa, H., Ito, T., Matsuda, K. I. and Kawata, M. (2001)
Dynamic changes in subcellular localization of mineralocorticoid receptor
in living cells: in comparison with glucocorticoid receptor using dual-color
labeling with green fluorescent protein spectral variants Mol Endocrinol
15, 1077-92.
Pearce, D., Naray-Fejes-Toth, A. and Fejes-Toth, G. (2002) Determinants
of subnuclear organization of mineralocorticoid receptor characterized
through analysis of wild type and mutant receptors J Biol Chem 277,
1451-6.
Phair, R. D. and Misteli, T. (2000) High mobility of proteins in the
mammalian cell nucleus Nature 404, 604-9.
Rai, D., Frolova, A., Frasor, J., Carpenter, A. E. and Katzenellenbogen,
B. S. (2005) Distinctive actions of membrane-targeted versus nuclear
localized estrogen receptors in breast cancer cells Mol Endocrinol 19,
1606-17.
Rayasam, G.V., Elbi, C., Walker, D. A., Wolford, R., Fletcher, T. M.,
Edwards, D. P. and Hager, G. L. (2005) Ligand-specific dynamics of the
progesterone receptor in living cells and during chromatin remodeling in
vitro Mol Cell Biol 25, 2406-18.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05003 | Page 8 of 9
Review Visualizing steroid hormone receptorsRazandi, M., Pedram, A., Merchenthaler, I., Greene, G. L. and Levin, E.
R. (2004) Plasma membrane estrogen receptors exist and functions as
dimers Mol Endocrinol 18, 2854-65.
Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D.,
Beaudouin, J., Ellenberg, J. and Gannon, F. (2003) Cyclic,
proteasome-mediated turnover of unliganded and liganded ERalpha on
responsive promoters is an integral feature of estrogen signaling Mol Cell
11, 695-707.
Salomonsson, M., Haggblad, J., O'Malley, B.W. and Sitbon, G. M. (1994)
The human estrogen receptor hormone binding domain dimerizes
independently of ligand activation J Steroid Biochem Mol Biol 48, 447-52.
Schaaf, M. J., Lewis-Tuffin, L. J. and Cidlowski, J. A. (2005)
Ligand-selective targeting of the glucocorticoid receptor to nuclear
subdomains is associated with decreased receptor mobility Mol Endocrinol
19, 1501-15.
Schaufele, F., Chang, C.Y., Liu, W., Baxter, J. D., Nordeen, S. K., Wan,
Y., Day, R. N. and McDonnell, D. P. (2000) Temporally distinct and
ligand-specific recruitment of nuclear receptor-interacting peptides and
cofactors to subnuclear domains containing the estrogen receptor Mol
Endocrinol 14, 2024-39.
Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman,
M. S., Ma, A. A., Miner, J. N. and Diamond, M. I. (2005) The structural
basis of androgen receptor activation: intramolecular and intermolecular
amino-carboxy interactions Proc Natl Acad Sci U S A 102, 9802-7.
Sprague, B. L., Pego, R. L., Stavreva, D. A. and McNally, J. G. (2004)
Analysis of binding reactions by fluorescence recovery after
photobleaching Biophys J 86, 3473-95.
Stavreva, D. A., Muller, W. G., Hager, G. L., Smith, C. L. and McNally, J.
G. (2004) Rapid glucocorticoid receptor exchange at a promoter is coupled
to transcription and regulated by chaperones and proteasomes Mol Cell
Biol 24, 2682-97.
Stenoien, D. L., Patel, K., Mancini, M. G., Dutertre, M., Smith, C. L.,
O'Malley, B.W. and Mancini, M. A. (2001a) FRAP reveals that mobility
of oestrogen receptor-alpha is ligand- and proteasome-dependent Nat
Cell Biol 3, 15-23.
Stenoien, D. L., Nye, A. C., Mancini, M. G., Patel, K., Dutertre, M.,
O'Malley, B.W., Smith, C. L., Belmont, A. S. and Mancini, M. A. (2001b)
Ligand-mediated assembly and real-time cellular dynamics of estrogen
receptor alpha-coactivator complexes in living cells Mol Cell Biol 21,
4404-12.
Tamrazi, A., Carlson, K. E., Rodriguez, A. L. and Katzenellenbogen, J.
A. (2005) Coactivator proteins as determinants of estrogen receptor
structure and function: spectroscopic evidence for a novel
coactivator-stabilized receptor conformation Mol Endocrinol 19, 1516-28.
Tamrazi, A., Carlson, K. E., Daniels, J. R., Hurth, K. M. and
Katzenellenbogen, J. A. (2002) Estrogen receptor dimerization: ligand
binding regulates dimer affinity and dimer dissociation rate Mol Endocrinol
16, 2706-19.
Tomura, A., Goto, K., Morinaga, H., Nomura, M., Okabe, T., Yanase, T.,
Takayanagi, R. and Nawata, H. (2001) The subnuclear three-dimensional
image analysis of androgen receptor fused to green fluorescence protein
J Biol Chem 276, 28395-401.
Tyagi, R. K., Lavrovsky, Y., Ahn, S. C., Song, C. S., Chatterjee, B. and
Roy, A. K. (2000) Dynamics of intracellular movement and
nucleocytoplasmic recycling of the ligand-activated androgen receptor in
living cells Mol Endocrinol 14, 1162-74.
Weatherman, R.V., Chang, C.Y., Clegg, N. J., Carroll, D. C., Day, R.
N., Baxter, J. D., McDonnell, D. P., Scanlan, T. S. and Schaufele, F.
(2002) Ligand-selective interactions of ER detected in living cells by
fluorescence resonance energy transfer Mol Endocrinol 16, 487-96.
www.nursa.org  NRS  | 2007 |  Vol. 5 |  DOI: 10.1621/nrs.05003 | Page 9 of 9
Review Visualizing steroid hormone receptors